Literature DB >> 25412725

Relapsing pityriasis rosea.

Francesco Drago1, Giulia Ciccarese, Alfredo Rebora, Aurora Parodi.   

Abstract

To assess the prevalence of relapses of pityriasis rosea (PR), a retrospective cohort study investigated all PR cases diagnosed in Genoa between 2000 and 2013 and followed them up to today. Of 570 cases, 21 (3.7%) relapsed. Most of them had a single episode, but 4 had two episodes and 2 had three episodes. The herald patch was always absent, size and number of the lesions were reduced, and duration was shorter than that of the primary episodes. Constitutional symptoms were present, though less severe than in the primary eruption. Most recurrences occurred within 1 year (16/21, 76.2%). Men outnumbered women and the mean age of the relapsing patients (20.3 years) was higher than that for the primary episode. A pathogenetic hypothesis is provided: since PR is associated with reactivation of human herpesvirus 6/7, a parallelism with other typical reactivating human herpesviruses (varicella zoster virus and Epstein-Barr virus) has been established.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25412725     DOI: 10.1159/000363568

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  6 in total

1.  Interventions for pityriasis rosea.

Authors:  Jose Contreras-Ruiz; Sandra Peternel; Carlos Jiménez Gutiérrez; Ivana Culav-Koscak; Ludovic Reveiz; Maria de Lourdes Silbermann-Reynoso
Journal:  Cochrane Database Syst Rev       Date:  2019-10-30

Review 2.  Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies?

Authors:  Antonio Chuh; Vijay Zawar; Gabriel F Sciallis; Werner Kempf; Albert Lee
Journal:  Infect Dis Rep       Date:  2016-03-21

3.  Pityriasis rosea in a patient with retrovirus infection: a reply.

Authors:  Giulia Ciccarese; Aurora Parodi; Francesca Drago; Astrid Herzum; Francesco Drago
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

4.  Recurrent pityriasis rosea: A case report.

Authors:  Ang Li; Ping Li; Yanqiong Li; Wenfei Li
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

Review 5.  Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis.

Authors:  Milton Rodriguez-Zuniga; Natalie Torres; Herney Garcia-Perdomo
Journal:  An Bras Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.896

6.  Efficacy and Safety of Indigo Naturalis in Combination with Narrow-Band Ultraviolet B for Treatment of Pityriasis Rosea: A Meta-Analysis.

Authors:  L Wang; Y N Xue; Z W Li; W Zhang; X P Ji; Z Fan; Y J Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-27       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.